Zai Lab is a Shanghai-based biopharmaceutical company that sells prescription medicines for cancer, autoimmune and infectious diseases. ZLAB reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 7 | Citigroup | Maintained | Buy |
Seasonality
How ZLAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in ZLAB in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZLAB is in one of them and how their past ZLAB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZLAB in an article yet. Here's the latest on the wider market.
About Zai Lab
Zai Lab is a biopharmaceutical company based in Shanghai that develops and sells prescription medicines. Its approved products treat conditions including ovarian cancer, generalized myasthenia gravis, glioblastoma, pneumonia and gastrointestinal stromal tumors. The products are sold across Greater China, where the company works with major medical centers and distributors. It also has a presence in the United States and a pipeline of additional candidates.
- Headquarters
- Shanghai
- Website
- zailaboratory.com ↗